ViferaXS raises €12M in Series A led by SPRIND and Huma to advance Phase II trial for chronic lymphocytic leukemia.
Amount Raised
€12 Million
Round Type
Series A
Baden WürttembergBiotechnologyHealth CareTherapeuticsInvestors
Description
ViferaXS, a clinical-stage biotechnology company developing peptide-based cancer immunotherapy, closed a €12 million Series A financing round led by SPRIND and Huma with participation from private investors. The proceeds will fund the company's lead Phase II clinical trial of CLLTAXS01 in chronic lymphocytic leukemia, as well as ongoing Phase I programs in acute myeloid leukemia and fibrolamellar carcinoma. The financing also supports team expansion and preclinical work in additional indications.
Quick answer
ViferaXS raised €12 Million in a Series A round, dated September 23, 2026. Investors: Huma and Sprind. ViferaXS is based in Baden Württemberg, Germany.
- How much did ViferaXS raise?
- ViferaXS raised €12 Million in a Series A round on September 23, 2026.
- Who invested in ViferaXS?
- Huma and Sprind are named as investors in this round.
- What does ViferaXS do?
- ViferaXS GmbH is a clinical-stage biotechnology company based in Tübingen, Germany, developing peptide-based cancer immunotherapies for hematologic malignancies and solid tumors.
- Where is ViferaXS based and how big is it?
- ViferaXS is based in Baden Württemberg, Germany. Fundz records about 2 employees.
- Who are the decision-makers at ViferaXS?
- Fundz holds 1 contact at ViferaXS, including the Consulting CMO to ViferaXS. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as ViferaXS that raised within 45 days of this round, from Fundz verified event records.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
- Alethio raised $90M (Series A) on November 5, 2026.
- MyoPax raised an undisclosed amount (Pre-Seed) on November 4, 2026.
- Biograil raised $22M on November 4, 2026.
- Emvena Therapeutics raised an undisclosed amount (Seed) on November 4, 2026.
- Thryv Therapeutics raised $30M (Series B) on November 3, 2026.
Who to call at ViferaXS, and when
A new round usually means ViferaXS is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ViferaXS raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ViferaXS, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ViferaXS. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ViferaXS raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansViferaXS raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.